The FDA, Unicure, and the Limits of Accelerated Approval

About this episode

Anish discusses the FDA's handling of Unicure's AMT-130 with med student and biotech investor Adu, exploring the implications of accelerated approval in the context of desperate patient populations.

Episode Summary Anish sits down with Adu, a med student and biotech investor, to work through the FDA's contested handling of Unicure's AMT-130 — a gene therapy for Huntington's disease delivered via stereotactic brain injection. They debate whether the underlying data justifies approval, why the agency's mid-course reversal has rattled the investor community, and what the Sarepta precedent should have taught everyone involved. The conversation broadens into a bigger question: given that desperate patient populations will always demand access to anything showing a signal, who is actually best positioned to make the call on whether a drug works — the FDA, the clinician, or the market? Chapter Markers 00:00 FDA approval of AMT-130 and investor reaction 01:16 Unmet need and the case for regulatory flexibility 02:37 Sarepta, Duchenne's, and the cost of approving under pressure 05:09 Accelerated approval done right: the Amylyx example 09:14 Debating the AMT-130 data and the historical control problem 13:53 Why stock price matters for trial funding 17:20 How Prasad could have changed FDA culture differently 19:37 The FDA's role from Kefauver-Harris to today 22:26 Competing Huntington's…

People in this episode

Host: Anish

Guest: Adu

Topics covered

• FDA approval
• gene therapy
• Huntington's disease
• accelerated approval
• biotech investment
• regulatory flexibility

Keywords

• FDA
• Unicure
• AMT-130
• gene therapy
• accelerated approval
• biotech
• Huntington's disease
• investor reaction
• regulatory flexibility

Mentioned in this episode

Organizations: FDA, Unicure, Sarepta, Amylyx, Prasad, Kefauver-Harris, Duchenne's, Huntington's, science journalism

Products: AMT-130

More episodes of The Doctor's Lounge

• The Atom Bomb Speaks: Tracy Høeg on COVID, Myocarditis, and the FDA From the Inside · June 10, 2026 · 1h 13m
• The ER Doc Who Quit the System - and Built His Own · June 6, 2026 · 1h 2m
• The Cholesterol Debate: What the Keto Influencers Get Right (and Wrong) · June 3, 2026 · 1h 1m
• Gaming the System: LTACHs, Guidelines, and the Evidence Problem in American Medicine · May 31, 2026 · 1h 5m
• Salty About Medical Education: Bryan Carmody on What the System Gets Wrong · May 23, 2026 · 1h 8m
• Free Markets, Private Equity, and the Moral Case for Medicine · May 17, 2026 · 1h 27m